WO2024023641 - METHODS OF TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITOR DOSING FIELD OF THE INVENTION
National phase entry:
Publication Number
WO/2024/023641
Publication Date
01.02.2024
International Application No.
PCT/IB2023/057314
International Filing Date
18.07.2023
Title **
[English]
METHODS OF TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITOR DOSING FIELD OF THE INVENTION
[French]
MÉTHODES ASSOCIÉES À L'ADMINISTRATION D'UN INHIBITEUR TRICYCLIQUE DE KARS DÉPENDANT DE AKR1C3 DE L'INVENTION
Applicants **
NOVARTIS AG
Inventors
FRYER, Christy
KATTENHORN, Lisa
MCLAUGHLIN, Margaret Elise
STONEHOUSE, Jeffrey
MAACKE, Heiko
L'EPICIER-SANSREGRET, Laurent
Priority Data
63/369,399
26.07.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5285 | |
| EPO | Filing, Examination, Granting | 102725 | |
| Japan | Filing, Examination, Granting | 4870 | |
| South Korea | Filing, Examination, Granting | 7758 | |
| USA | Filing, Examination, Granting | 28190 |
Total:
148,828
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to methods of identifying a subject for treatment with or treating a subject with a tricyclic AKR1C3 dependent KARS inhibitor of formula (I), or a pharmaceutically acceptable salt thereof. The methods may comprise determining in a subject sample a level of at least one of the following biomarkers: AKR1C3, NFE2L2, KEAP1, or CUL3, wherein an elevated level of the biomarker identifies the subject as being in need of treatment; or detecting in a subject sample a somatic mutation in at least one of the following genes: NFE2L2, KEAP1, or CUL3, wherein detecting the somatic mutation identifies the subject as being in need of treatment.[French]
La présente invention concerne des méthodes d'identification d'un sujet à des fins de traitement, ou des méthodes de traitement d'un sujet avec un inhibiteur tricyclique de KARS dépendant de AKR1C3 de formule (I), ou avec un sel de qualité pharmaceutique de celui-ci. Les méthodes peuvent comprendre la détermination, dans un échantillon prélevé chez le sujet, d'un niveau d'au moins l'un des biomarqueurs suivants : AKR1C3, NFE2L2, KEAP1 ou CUL3, un niveau élevé du biomarqueur indiquant que le sujet a besoin d'un traitement ; ou la détection dans un échantillon prélevé chez le sujet d'une mutation somatique touchant au moins l'un des gènes suivants : NFE2L2, KEAP1 ou CUL3, la détection de la mutation somatique indiquant que le sujet a besoin d'un traitement.